Advanced Cell Technology, Inc.

Advanced Cell Technology Receives FDA Clearance for the First Clinical Trial

Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC) announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.

Advanced Cell Technology Awarded Broad Patent for Production of Retinal Pigment Epithelial Cells

Key Patent Covers Fundamental Methods for Producing RPE Cells from Embryonic Stem Cells Including IP Used in Phase I Trial to Treat Patients with Stargardt's Macular Dystrophy.

NIH Approves Advanced Cell Technology's Stem Cell Line for Federal Funding

Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC) announced today that human embryonic stem cell (hESC) line MA135 was unanimously approved for federal funding at the 100th Meeting of the Advisory Committee to the Director (ACD) National Institutes of Health (NIH). In addition to MA135, seven additional stem cell lines derived at ACT are currently under review by the NIH. Five of these lines were produced without using ACT's proprietary single-blastomere "embryo-safe" technology. The federal funding could accelerate the company's clinical activities.

Advanced Cell Technology’s Studies to Support Phase I Multicenter Trial of Patients with Stargardt’s Macular Dystrophy Demonstrate Excellent Safety Profile

Advanced Cell Technology's CEO William M. Caldwell IV Interviewed on Bloomberg Radio

WORCESTER -- Advanced Cell Technology, Inc. (OTCBB: ACTC), a biotechnology company applying cellular technology in the field of regenerative medicine, announced that company Chairman and Chief Executive Officer William M. Caldwell IV was interviewed yesterday on Bloomberg Radio's popular mid-day program, The Hays Advantage, hosted by Kathleen Hays.

Agency Proposes U.S.-Paid Research on Stem Cells

The National Institutes of Health is proposing to expand its definition of human embryonic stem cells, enabling the university researchers it finances to work with cells derived from a very early human egg.

NIH Seeks to Expand the Definition of 'human Embryonic Stem Cell'

The National Institutes of Health is proposing a small change to the definition of "human embryonic stem cell" that could have a big effect on their long-term ability to lead to cures for a variety of diseases.